Oncogenes in high grade serous adenocarcinoma of the ovary
Pacharla Manasa1, C. Sidhanth1, Syama Krishnapriya1, Sekar Vasudevan1 and Trivadi S. Ganesan1
1 Laboratory for Cancer Biology, Department of Medical Oncology and Clinical Research Cancer Institute (WIA), Chennai, India
Correspondence:
Trivadi S. Ganesan, email:
Keywords: oncogenes, ovarian cancer, high grade serous adenocarcinoma of the ovary, TCGA, copy number alterations
Received: March 11, 2020 Accepted: October 15, 2020 Published: November 11, 2020
Abstract
High grade serous ovarian cancer is characterized by relatively few mutations occurring at low frequency, except in TP53. However other genetic aberrations such as copy number variation alter numerous oncogenes and tumor suppressor genes. Oncogenes are positive regulators of tumorigenesis and play a critical role in cancer cell growth, proliferation, and survival. Accumulating evidence suggests that they are crucial for the development and the progression of high grade serous ovarian carcinoma (HGSOC). Though many oncogenes have been identified, no successful inhibitors targeting these molecules and their associated pathways are available. This review discusses oncogenes that have been identified recently in HGSOC using different screening strategies. All the genes discussed in this review have been functionally characterized both in vitro and in vivo and some of them are able to transform immortalized ovarian surface epithelial and fallopian tube cells upon overexpression. However, it is necessary to delineate the molecular pathways affected by these oncogenes for the development of therapeutic strategies.